Your browser doesn't support javascript.
loading
High-risk human papilloma virus status & outcomes for penile squamous cell carcinoma: A single institution experience.
Tekin, Burak; Cubilla, Antonio L; Cheville, John C; Smith, Carin Y; Jenkins, Sarah M; Dasari, Surendra; Enninga, Elizabeth Ann L; Norgan, Andrew P; Menon, Santosh; Whaley, Rumeal D; Hernandez, Loren Herrera; Jimenez, Rafael E; Garcia, Joaquin J; Thompson, R Houston; Leibovich, Bradley C; Karnes, R Jeffrey; Boorjian, Stephen A; Pagliaro, Lance C; Erickson, Lori A; Guo, Ruifeng; Gupta, Sounak.
Afiliación
  • Tekin B; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Tekin.Burak@mayo.edu.
  • Cubilla AL; Instituto de Patología e Investigación, Universidad Nacional de Asunción, Asunción, Paraguay. Electronic address: antoniocubillaramos@gmail.com.
  • Cheville JC; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: cheville.john@mayo.edu.
  • Smith CY; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MM, USA. Electronic address: Smith.Carin@mayo.edu.
  • Jenkins SM; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MM, USA. Electronic address: Jenkins.Sarah@mayo.edu.
  • Dasari S; Division of Biomedical Statistics & Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. Electronic address: Dasari.Surendra@mayo.edu.
  • Enninga EAL; Departments of Immunology, Obstetrics & Gynecology, Mayo Clinic, Rochester, MN, USA. Electronic address: Enninga.ElizabethAnn@mayo.edu.
  • Norgan AP; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Norgan.Andrew@mayo.edu.
  • Menon S; Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India. Electronic address: mensantosh@gmail.com.
  • Whaley RD; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Whaley.Rumeal@mayo.edu.
  • Hernandez LH; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: herrerahernandez.loren@mayo.edu.
  • Jimenez RE; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: jimenez.rafael@mayo.edu.
  • Garcia JJ; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: garcia.joaquin@mayo.edu.
  • Thompson RH; Department of Urology, Mayo Clinic, Rochester, MN, USA. Electronic address: thompson.robert@mayo.edu.
  • Leibovich BC; Department of Urology, Mayo Clinic, Rochester, MN, USA. Electronic address: leibovich.bradley@mayo.edu.
  • Karnes RJ; Department of Urology, Mayo Clinic, Rochester, MN, USA. Electronic address: Karnes.R@mayo.edu.
  • Boorjian SA; Department of Urology, Mayo Clinic, Rochester, MN, USA. Electronic address: boorjian.stephen@mayo.edu.
  • Pagliaro LC; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: Pagliaro.Lance@mayo.edu.
  • Erickson LA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Erickson.Lori@mayo.edu.
  • Guo R; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Guo.Ruifeng@mayo.edu.
  • Gupta S; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: gupta.sounak@mayo.edu.
Hum Pathol ; 150: 9-19, 2024 Jun 21.
Article en En | MEDLINE | ID: mdl-38909709
ABSTRACT

OBJECTIVES:

There is a paucity of data on North American cohorts of patients with penile squamous cell carcinoma (pSCC). Herein, we aimed to assess the sensitivity of various modalities to identify human papillomavirus (HPV) status, determine the prevalence of high-risk HPV-positivity, and evaluate the prognostic impact of relevant clinicopathologic variables.

METHODS:

Patients with pSCC (n = 121) consecutively treated with partial/total penectomy (2000-2022) at a single institution were included. HPV status (based on immunohistochemistry [IHC], in situ hybridization [ISH], and panviral metagenomic sequencing [PMS]), histologic features, and outcomes were reviewed. Outcome events included death due to disease and progression.

RESULTS:

The majority of patients were white (105/121, 86.8%). Thirty-seven (30.6%) were high-risk HPV-positive, and morphologic evaluation had a sensitivity of 97.3% (95% confidence interval [CI], 86.2-99.5) for predicting high-risk HPV status compared to IHC/ISH/PMS. Disease progression was more common among high-risk HPV-negative compared to high-risk HPV-positive patients (HR 2.74, CI 1.12-8.23, P = 0.03). Moreover, among high-risk HPV-negative patients, those with moderate-poorly differentiated tumors had increased disease-specific mortality (32.6%, CI 17.1-48.1) compared to those with well-differentiated tumors (0%). Among high-risk HPV-positive patients, those with basaloid morphology had lower disease-specific mortality (0% vs 14.4%, CI 0.0-33.1).

CONCLUSIONS:

We demonstrate high-risk HPV-positivity in approximately one-third of patients with pSCC. Morphologic evaluation alone had a high sensitivity in correctly determining HPV status. Our results suggest that high-risk HPV status and morphologic features (differentiation in high-risk HPV-negative, and basaloid subtype in high-risk HPV-positive pSCC) may have prognostic value.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Hum Pathol Asunto de la revista: PATOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Hum Pathol Asunto de la revista: PATOLOGIA Año: 2024 Tipo del documento: Article